Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Carlsmed (CARL) Gains from Investment Securities (2024 - 2025)

Carlsmed (CARL) has disclosed Gains from Investment Securities for 2 consecutive years, with -$1.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 251.42% year-over-year to -$1.8 million, compared with a TTM value of $1.2 million through Dec 2024, changed N/A, and an annual FY2025 reading of -$17000.0, down 101.42% over the prior year.
  • Gains from Investment Securities was -$1.8 million for Q4 2025 at Carlsmed, down from $1.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.2 million in Q3 2025 and bottomed at -$1.8 million in Q4 2025.